Merck HCV Drugs Hit Trial Goals, Win Fast FDA Review
Big pharma Merck (MRK) released late-stage data Wednesday on its hepatitis C regime that met Wall Street’s expectations, and also announced that the FDA had awarded it breakthrough therapy designation for certain patient groups. Merck’s 14 studies were among a passel of newly released abstracts for presentations at the annual meeting of the European Association for the Study of Liver (EASL), convening April 22 to 26 in Vienna. The combination